文献速递胸部肿瘤

奥希替尼治疗经治T790M阳性晚期非小细胞肺癌:AURA研究II期扩展部分

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
PubMed 文献 · J Clin Oncol · 2017-02-21

AURA研究II期扩展部分纳入201例经EGFR-TKI治疗后进展的EGFR突变T790M阳性晚期非小细胞肺癌患者,每日口服奥希替尼80 mg。可评估患者198例,客观缓解率为62%(95%CI 54%~68%),疾病控制率90%(95%CI 85~94),中位无进展生存期12.3个月(95%CI 9.5~13.8),中位缓解持续时间15.2个月(95%CI 11.3~不可计算)。

要点

  • 奥希替尼80 mg每日一次用于EGFR-TKI经治T790M阳性晚期NSCLC,客观缓解率62%。
  • 中位无进展生存期12.3个月,中位缓解持续时间15.2个月。
  • 常见可能相关不良事件为腹泻(43%)和皮疹(40%),≥3级均<1%;间质性肺病8例(4%),其中5级3例。

核心结论

  • 在EGFR-TKI治疗后进展的EGFR突变T790M阳性晚期非小细胞肺癌患者中,奥希替尼提供高客观缓解率、令人鼓舞的无进展生存期和持久缓解。

研究设计与样本

  • AURA(NCT01802632)是一项I/II期临床试验,本文报告其II期扩展部分结果。
  • 患者为经EGFR-TKI预治疗的EGFR突变且T790M阳性晚期非小细胞肺癌,每日接受奥希替尼80 mg。
  • T790M状态由最近一次疾病进展后采集的肿瘤样本经中心检测确认。
  • 允许无症状、稳定且无需糖皮质激素的中枢神经系统转移患者入组。
  • 主要终点为独立影像学评估的客观缓解率,次要终点包括疾病控制率、缓解持续时间、无进展生存期和安全性,患者报告结局为探索性目标。

主要发现

  • 共201例患者接受治疗,数据截止日期(2015年11月1日)时中位治疗持续时间为13.2个月。
  • 可评估患者198例,客观缓解率为62%(95%CI 54%~68%),疾病控制率为90%(95%CI 85~94)。
  • 122例缓解患者的中位缓解持续时间为15.2个月(95%CI 11.3~不可计算)。
  • 中位无进展生存期为12.3个月(95%CI 9.5~13.8)。
  • 研究者评估的最常见可能相关不良事件为腹泻(43%;≥3级<1%)和皮疹(分组术语;40%;≥3级<1%),间质性肺病(分组术语)报告8例(4%;1级2例,3级3例,5级3例)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing ( EGFRm) and T790M resistance mutations. AURA (NCT01802632) is a phase I/II clinical trial to determine the dose, safety, and efficacy of osimertinib. This article reports the results from the phase II extension component. Patients and Methods Patients with EGFR-TKI-pretreated EGFRm- and T790M-positive advanced non-small-cell lung cancer (NSCLC) received once-daily osimertinib 80 mg. T790M status was confirmed by central testing from a tumor sample taken after the most recent disease progression. Patients with asymptomatic, stable CNS metastases that did not require corticosteroids were allowed to enroll. The primary end point was objective response rate (ORR) by independent radiology assessment. Secondary end points were disease control rate, duration of response, progression-free survival (PFS), and safety. Patient-reported outcomes comprised an exploratory objective. Results In total, 201 patients received treatment, with a median treatment duration of 13.2 months at the time of data cutoff (November 1, 2015). In evaluable patients (n = 198), ORR was 62% (95% CI, 54% to 68%), and the disease control rate was 90% (95% CI, 85 to 94). Median duration of response in 122 responding patients was 15.2 months (95% CI, 11.3 to not calculable). Median PFS was 12.3 months (95% CI, 9.5 to 13.8). The most common possibly causally related adverse events (investigator assessed) were diarrhea (43%; grade ≥ 3, < 1%) and rash (grouped terms; 40%; grade ≥ 3, < 1%). Interstitial lung disease (grouped terms) was reported in eight patients (4%; grade 1, n = 2; grade 3, n = 3; grade 5, n = 3). Conclusion In patients with EGFRm T790M advanced NSCLC who progress after EGFR-TKI treatment, osimertinib provides a high ORR, encouraging PFS, and durable response.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017. PMID: 28221867. doi:10.1200/JCO.2016.70.3223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。